Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects Who Have Chronic HCV-1/HIV-1 Co-Infection and Are Treatment-Naive for Hepatitis C.

Next Previous
Trial Profile

A Phase 2a, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects Who Have Chronic HCV-1/HIV-1 Co-Infection and Are Treatment-Naive for Hepatitis C.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telaprevir (Primary) ; Atazanavir; Efavirenz; Emtricitabine; Lamivudine; Peginterferon alfa-2a; Ribavirin; Ritonavir; Tenofovir dipivoxil fumarate
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals

Most Recent Events

  • 12 Nov 2012 Final results (SVR24) were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
  • 23 Mar 2012 Actual patient number changed from 62 to 68 as reported by ClinicalTrials.gov.
  • 23 Mar 2012 Actual end date (1 Mar 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top